ARRIVENT BIOPHARMA, INC. Net Income (Loss) Available to Common Stockholders, Diluted
ARRIVENT BIOPHARMA, INC. (AVBP) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$49.89 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-12
- ARRIVENT BIOPHARMA, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$49.89M.
- ARRIVENT BIOPHARMA, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$43.32M.
- ARRIVENT BIOPHARMA, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was -$35.54M.
- ARRIVENT BIOPHARMA, INC. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$34.98M.
- ARRIVENT BIOPHARMA, INC. net income (loss) available to common stockholders, diluted for fiscal 2025 was -$166.31M.
- ARRIVENT BIOPHARMA, INC. net income (loss) available to common stockholders, diluted for fiscal 2024 was -$80.49M.
- ARRIVENT BIOPHARMA, INC. net income (loss) available to common stockholders, diluted for fiscal 2023 was -$69.33M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$49.89M 10-Q · filed 2026-08-12 | -$93.21M 10-Q · filed 2026-08-12 | -$128.76M derived: sum of 3 quarters · filed 2026-08-12 | -$163.74M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$43.32M 10-Q · filed 2026-05-11 | -$78.86M derived: sum of 2 quarters · filed 2026-05-11 | -$113.84M derived: sum of 3 quarters · filed 2026-05-11 | -$145.24M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$35.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$70.52M derived: sum of 2 quarters · filed 2026-03-05 | -$101.92M derived: sum of 3 quarters · filed 2026-08-12 | -$166.31M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$34.98M 10-Q · filed 2025-11-10 | -$66.38M derived: sum of 2 quarters · filed 2026-08-12 | -$130.76M 10-Q · filed 2025-11-10 | -$151.40M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$31.40M 10-Q · filed 2026-08-12 | -$95.79M 10-Q · filed 2026-08-12 | -$116.42M derived: sum of 3 quarters · filed 2026-08-12 | -$136.98M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$64.39M 10-Q · filed 2026-05-11 | -$85.02M derived: sum of 2 quarters · filed 2026-05-11 | -$105.58M derived: sum of 3 quarters · filed 2026-05-11 | -$127.46M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$20.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$41.20M derived: sum of 2 quarters · filed 2026-03-05 | -$63.07M derived: sum of 3 quarters · filed 2026-03-05 | -$80.49M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$20.56M 10-Q · filed 2025-11-10 | -$42.44M derived: sum of 2 quarters · filed 2025-11-10 | -$59.85M 10-Q · filed 2025-11-10 | -$81.05M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$21.87M 10-Q · filed 2025-08-11 | -$39.29M 10-Q · filed 2025-08-11 | -$60.48M derived: sum of 3 quarters · filed 2025-08-11 | -$74.89M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$17.42M 10-Q · filed 2025-05-12 | -$38.61M derived: sum of 2 quarters · filed 2025-05-12 | -$53.01M derived: sum of 3 quarters · filed 2025-05-12 | -$74.58M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$21.19M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$35.59M derived: sum of 2 quarters · filed 2025-03-03 | -$57.16M derived: sum of 3 quarters · filed 2025-03-03 | -$69.33M 10-K · filed 2025-03-03 |
| 2023-09-30 | -$14.40M 10-Q · filed 2024-11-14 | -$35.97M derived: sum of 2 quarters · filed 2024-11-14 | -$48.14M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | -$21.57M 10-Q · filed 2024-08-14 | -$33.74M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | -$12.17M 10-Q · filed 2024-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |